Related Experiment Video
Updated: Jun 18, 2025
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico
Sergio Sauri-Suarez1, Sandra Quiñones2, Manuel De la Maza-Flores3
1ISSSTE National Medical Center 20 de noviembre, Mexico City, Mexico Internal Medicine Department, IMSS HGZ 1A Venados, Mexico City, Mexico.
Background:
Cladribine shows efficacy in multiple sclerosis (MS), but Latin American (LATAM) real-world data is limited, despite potential sociodemographic variations.
Objective:
Investigate baseline characteristics and clinical response in highly active MS patients in Mexico, identifying predictors of early treatment response.
Method:
A multicenter cohort study analyzed retrospective data from individuals with "highly active" MS in the Cladribine Patient Support Program across 11 Mexican clinics. Criteria included one-year prior treatment with another disease-modifying treatment and recent relapse with specific MRI findings. Primary outcomes focused on achieving NEDA-3 status after 12 months.
Results:
In the follow-up, 67.5% maintained NEDA-3 status. Baseline EDSS scores decreased significantly from 1.50 to 1.00 (p = 0.011), with no confirmed disability worsening. No significant differences were observed between NEDA-3 achievers and non-achievers in demographic and clinical variables. No severe adverse events were reported.
Conclusion:
Cladribine showed early and effective control of active MS in Mexican patients, demonstrating a secure profile with minimal adverse events. This study provides valuable real-world evidence in the LATAM context.
